<DOC>
	<DOCNO>NCT01452607</DOCNO>
	<brief_summary>A study determine safety , tolerability , pharmacokinetics SPI-1005 capsule healthy adult .</brief_summary>
	<brief_title>Study Evaluate Safety Pharmacokinetics SPI-1005</brief_title>
	<detailed_description />
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Ebselen</mesh_term>
	<criteria>Healthy adult male female subject Within 15 % ideal weight ( Table `` Desirable Weights Adults , '' Metropolitan Life Insurance Company , 1983 ) Medically healthy subject clinically insignificant screen result ( laboratory profile , medical history , ECGs , physical exam ) ; Voluntarily consent participate study ; Females childbearing potential either sexually inactive ( abstinent ) 14 day prior screen throughout study use one follow acceptable birth control method : Intrauterine device ( IUD ) place least 3 month prior study ; Barrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; Stable hormonal contraceptive least 3 month prior study completion study ; Surgical sterilization ( vasectomy ) partner least 6 month prior study . Females nonchildbearing potential surgically sterile ( bilateral tubal ligation surgery least 6 month prior study , hysterectomy , bilateral oophorectomy least 2 month prior study ) . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , otologic , psychiatric disease ; History presence alcoholism drug abuse within past 2 year ; Hypersensitivity idiosyncratic reaction compound related ebselen ; Use prescription medication within 14 day ( exception hormonal contraceptive ) prior study ; Use overthecounter medication include vitamin , herbal preparation , antacid , cough cold remedy , etc. , within 7 day prior study ; Use drug substance know strong inhibitor inducer cytochrome P450 enzyme within 28 day prior dose ; Abnormal diet ( reason ) 30 day prior dose ; Donation whole blood within 56 day prior study ; Plasma donation within 7 day prior study ; Participation another clinical trial within 30 day prior study ; Female subject pregnant lactating ; Hemoglobin &lt; 12.0 g/dL ; Orthostatic vital sign result : A pulse increase 30 beat per minute 3 minute stand ( compare semirecumbent pulse rate ) ; A pulse rate great 100 bpm 3 minute stand ; A drop systolic blood pressure decrease least 20 mm Hg ; A diastolic blood pressure decrease least 10 mm Hg within 3 minute stand ( compare semirecumbent blood pressure ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Ebselen</keyword>
</DOC>